XETRA

EQS-News: init innovation in traffic systems SE: Status of the share buyback: 08 to 12 May 2023

Retrieved on: 
Tuesday, May 16, 2023

init innovation in traffic systems SE: Status of the share buyback: 08 to 12 May 2023

Key Points: 
  • init innovation in traffic systems SE: Status of the share buyback: 08 to 12 May 2023
    The issuer is solely responsible for the content of this announcement.
  • In the period from 08 May to 12 May 2023, init innovation in traffic systems SE (ISIN DE0005759807) acquired 3,666 treasury shares at a value of EUR 145,250.30.
  • The acquisition was carried out by the assigned bank via the stock exchange (XETRA).
  • Information about individual transactions and daily trading volumes is published online under the following link:

Newron Presents Exciting New Data From Study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, May 15, 2023

The study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.

Key Points: 
  • The study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • 97% of patients completed six weeks of treatment, and more than 90% of the completers chose to continue with evenamide treatment into the long-term extension study (study 015).
  • Final efficacy and safety results from all 161 patients at the six-week primary endpoint of Study 014 were announced in March 2023 .
  • The multi-modal-benefits observed across various domains with evenamide also validate extensive academic research, suggesting that TRS results from excessive glutamate signalling.

EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, May 15, 2023

The study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.

Key Points: 
  • The study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • 97% of patients completed six weeks of treatment, and more than 90% of the completers chose to continue with evenamide treatment into the long-term extension study (study 015).
  • Final efficacy and safety results from all 161 patients at the six-week primary endpoint of Study 014 were announced in March 2023.
  • The multi-modal-benefits observed across various domains with evenamide also validate extensive academic research, suggesting that TRS results from excessive glutamate signalling.

EQS-News: Advanced Blockchain announces new project

Retrieved on: 
Tuesday, May 9, 2023

Mai 2023 - Advanced Blockchain AG (“AB”, Scale Frankfurt, primary market Düsseldorf, XETRA: ISIN DE000A0M93V6), a leading incubator, architect and investor for the blockchain industry, announces its latest product innovation: AB Capital AI.

Key Points: 
  • Mai 2023 - Advanced Blockchain AG (“AB”, Scale Frankfurt, primary market Düsseldorf, XETRA: ISIN DE000A0M93V6), a leading incubator, architect and investor for the blockchain industry, announces its latest product innovation: AB Capital AI.
  • This revolutionary product is a data aggregator that employs state-of-the-art AI technology to deliver automated token selection and research.
  • peaq also integrated with Fetch.ai for AI-based process automation, and Fraunhofer-led AI project will store EV battery digital twins on peaq network.
  • The Panoptic team participated in the Cornell Blockchain conference and held a well-received public event where they showcased their product demo.

EQS-News: init innovation in traffic systems SE: Status of the share buyback: 02 to 05 May 2023

Retrieved on: 
Tuesday, May 9, 2023

init innovation in traffic systems SE: Status of the share buyback: 02 to 05 May 2023

Key Points: 
  • init innovation in traffic systems SE: Status of the share buyback: 02 to 05 May 2023
    The issuer is solely responsible for the content of this announcement.
  • In the period from 02 May to 05 May 2023, init innovation in traffic systems SE (ISIN DE0005759807) acquired 3,829 treasury shares at a value of EUR 121,260.61.
  • The acquisition was carried out by the assigned bank via the stock exchange (XETRA).
  • Information about individual transactions and daily trading volumes is published online under the following link:

EQS-News: init innovation in traffic systems SE: Status of the share buyback 27 and 28 April 2023

Retrieved on: 
Wednesday, May 3, 2023

init innovation in traffic systems SE: Status of the share buyback 27 and 28 April 2023

Key Points: 
  • init innovation in traffic systems SE: Status of the share buyback 27 and 28 April 2023
    The issuer is solely responsible for the content of this announcement.
  • In the period from 27 April to 28 April 2023, init innovation in traffic systems SE (ISIN DE0005759807) acquired 1,864 treasury shares at a value of EUR 58,812.16.
  • The acquisition was carried out by the assigned bank via the stock exchange (XETRA).
  • Information about individual transactions and daily trading volumes is published online under the following link:

Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Wednesday, May 3, 2023

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present six posters in various presentation formats at the upcoming 34th CINP World Congress of Neuropsychopharmacology, taking place 7-10 May 2023 at the Fairmont The Queen Elizabeth hotel in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) taking place 11-15 May 2023 at The Westin Harbour Castle in Toronto, Ontario, Canada.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present six posters in various presentation formats at the upcoming 34th CINP World Congress of Neuropsychopharmacology, taking place 7-10 May 2023 at the Fairmont The Queen Elizabeth hotel in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) taking place 11-15 May 2023 at The Westin Harbour Castle in Toronto, Ontario, Canada.
  • The posters and presentations will feature first-time disclosures of additional results from study 014/015, an international, randomized, open label, rater-blinded study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS not responding to their current antipsychotic medication.
  • These results offer further analyses of the multidimensional efficacy of glutamate release modification in patients with TRS and the characteristics of early and late responders in patients with TRS, thus deepening the understanding of the potential long-term benefits an innovative add-on therapy that modifies glutamate release could offer to TRS patients.
  • “Evenamide Added On To Antipsychotics In Patients With TRS Is Associated With Significant Efficacy: Results From A Pilot, 6-week, Phase 2 Study”
    “Characteristics Of Early And Late Responders To Evenamide Add-on In TRS Patients Not Responding To An Antipsychotic: Results From A Phase 2 Study”

EQS-News: Advanced Blockchain with preliminary figures for 2022

Retrieved on: 
Wednesday, May 3, 2023

3 May 2023 – Advanced Blockchain AG (“AB”, Scale Frankfurt, primary market Düsseldorf, XETRA: ISIN DE000A0M93V6), a leading incubator, architect and investor for the blockchain industry announces, despite of massively challenging market environments, only a slight decrease in Net Sales, according to preliminary and unaudited figures.

Key Points: 
  • 3 May 2023 – Advanced Blockchain AG (“AB”, Scale Frankfurt, primary market Düsseldorf, XETRA: ISIN DE000A0M93V6), a leading incubator, architect and investor for the blockchain industry announces, despite of massively challenging market environments, only a slight decrease in Net Sales, according to preliminary and unaudited figures.
  • According to these figures, Net Sales came out at 17.69m € (FY 2022: 17.98m €), EBITDA stood at more than 580k € (FY 2022: 6.3m €) and EBIT at more than 560k € (FY 2022: 6.2m €).
  • Net Cash stood at roughly 4.3m € at the end of December 2022.
  • Simon Telian, CEO of AB comments: “Our investments and our group strategy showed impressive crisis resilience in 2022 on top level.

EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Wednesday, May 3, 2023

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The posters and presentations will feature first-time disclosures of additional results from study 014/015, an international, randomized, open label, rater-blinded study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS not responding to their current antipsychotic medication.
  • These results offer further analyses of the multidimensional efficacy of glutamate release modification in patients with TRS and the characteristics of early and late responders in patients with TRS, thus deepening the understanding of the potential long-term benefits an innovative add-on therapy that modifies glutamate release could offer to TRS patients.
  • “Evenamide Added On To Antipsychotics In Patients With TRS Is Associated With Significant Efficacy: Results From A Pilot, 6-week, Phase 2 Study”
    “Characteristics Of Early And Late Responders To Evenamide Add-on In TRS Patients Not Responding To An Antipsychotic: Results From A Phase 2 Study”

Newron Announces Senior Management Team Changes

Retrieved on: 
Tuesday, May 2, 2023

Roberto Galli, Vice President Finance since 2012, has been promoted to Chief Financial Officer as of July 1, 2023.

Key Points: 
  • Roberto Galli, Vice President Finance since 2012, has been promoted to Chief Financial Officer as of July 1, 2023.
  • At the same time, we warmly welcome Laura to the Senior Management Team at Newron and look forward to working with her in the future.
  • He joined Newron in November 2002 and has held several management positions within the Finance Department before being appointed Vice President Finance in June 2012.
  • Roberto was involved in the Company’s IPO, strategic corporate transactions, and was instrumental in finalizing the EIB funding facility.”